数据表1_病例报告：卵巢癌中BRCA1和BRIP1 vs BRCA1和BRCA2种系双杂合性的临床影响：一项比较案例研究

数据集获取（Figshare）

• 源站标题：Data Sheet 1_Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study.pdf
• DOI：10.3389/fonc.2025.1614373.s002
• 发布日期：2025-07-24
• 文件数：1 个
• 文件总体积：786.32 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Case_Report_Clinical_impact_of_BRCA1_and_BRIP1_vs_BRCA1_and_BRCA2_germline_double_heterozygosity_in_ovarian_cancer_a_comparative_case_study_pdf/29633294

命令行下载

curl -L -o "Data Sheet 1_Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case .pdf" "https://ndownloader.figshare.com/files/56510471"

文件清单

• Data Sheet 1_Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case .pdf（786.32 KB）

文件总体积 786.32 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Ovarian cancer (OC) is a highly heterogeneous malignancy influenced by germline genetic factors, with BRCA1/2 mutations being well-established risk factors. Germline double heterozygosity (GDH), particularly involving rare combinations, remains poorly understood. This study presents the first report of BRCA1/BRIP1 GDH in a case of Chinese OC patients and compares their clinical characteristics and treatment responses to a patient with BRCA1/BRCA2 GDH. The BRCA1/BRIP1 GDH patient is a 46-year-old female diagnosed with advanced ovarian adenocarcinoma at clinical stage FIGO IVB, exhibited severe chemotherapy-induced toxicity and postoperative complications, including chylous leakage. In contrast, the BRCA1/BRCA2 GDH patient is a 44-year-old female with high-grade serous ovarian cancer at clinical stage FIGO IIIC, tolerated chemotherapy well. Both patients experienced clinical benefit from Olaparib maintenance therapy. Genetic testing confirmed pathogenic variants in both cases, revealing distinct clinical trajectories influenced by different GDH profiles. Our findings suggest that different GDH combinations may influence chemotherapy tolerance and therapeutic effectiveness in OC. BRCA1/BRIP1 GDH patients may require personalized dose adjustments to mitigate toxicity and optimize efficacy. This study underscores the clinical significance of GDH heterogeneity and the importance of comprehensive genetic testing for guiding individualized treatment strategies. Future research should focus on expanding sample sizes and conducting in-depth functional analyses to further clarify the clinical implications of different GDH types, ultimately refining treatment approaches for GDH-associated OC.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2025.1614373.s002（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Case_Report_Clinical_impact_of_BRCA1_and_BRIP1_vs_BRCA1_and_BRCA2_germline_double_heterozygosity_in_ovarian_cancer_a_comparative_case_study_pdf/29633294）。